Authors

• Fara Brasó‐Maristany (ORCID: https://orcid.org/0000-0001-5440-9643)
• Melissa E. Hughes (ORCID: https://orcid.org/0000-0001-6190-9101)
• Guillermo Villacampa (ORCID: https://orcid.org/0000-0003-4868-6585)
• Elizabeth A. Mittendorf (ORCID: https://orcid.org/0000-0002-9762-8536)
• Nancy U. Lin (ORCID: https://orcid.org/0000-0003-2263-5413)
• Olivia Cunningham
• Nabihah Tayob (ORCID: https://orcid.org/0000-0001-6088-167X)
• Ashka Patel (ORCID: https://orcid.org/0009-0004-6128-5510)
• Olga Martínez‐Sáez (ORCID: https://orcid.org/0000-0001-8686-0236)
• Sara M. Tolaney (ORCID: https://orcid.org/0000-0002-5940-8671)
• Laia Paré (ORCID: https://orcid.org/0000-0002-4904-558X)
• Tari A. King (ORCID: https://orcid.org/0000-0003-3602-2351)
• Patricia Villagrasa (ORCID: https://orcid.org/0000-0002-8662-3641)
• Paolo Tarantino (ORCID: https://orcid.org/0000-0001-8686-0228)
• E. Sanfeliu Torres
• Mercedes Marín‐Aguilera (ORCID: https://orcid.org/0000-0002-2205-3459)
• Tianyu Li (ORCID: https://orcid.org/0000-0003-2324-6452)
• Aleix Prat
• Ruby Guo
• Beyza Koca (ORCID: https://orcid.org/0000-0002-8695-4424)

Institutions

• Brigham and Women's Hospital (US)
• Harvard University (US)
• Hospital Clínic de Barcelona (ES)
• Dana-Farber Cancer Institute (US)
• Oryzon Genomics (Spain) (ES)
• Vall d'Hebron Institute of Oncology (ES)

Publication Details

Journal

Journal of Clinical Oncology

Published

2025-05-28

DOI

https://doi.org/10.1200/jco.2025.43.16_suppl.553

Primary Topic

Cancer Immunotherapy and Biomarkers

Type

article

Field-Weighted Citation Impact

0.00